ECCO 2022

Is the continuation of combination therapy the key to…

The potential of histology in Crohn´s disease and how…

Combination trials open a new door in IBD treatment

Light at the end of the Pouchitis track

Microbiota manipulation: Still a lot to learn

FMT is not a promising option for UC patients

Withdrawal of infliximab or anti-metabolite therapy in…

Is the speedity of the steroid tapering important…

Combination of biologics - finally arrived in IBD!?

Infliximab withdrawl leeds to a higher risk of…

SPARE study in ECCO 2022

Will we improve the management of IBD by combining…

Filgotinib for fistulizing disease

The first combination therapy trial

Combination with different classes of drugs in moderate…

How to deescalate treatment in CD?

Is stopping of therapy an option in CD?

Combination of biologics

Proactive TDM

A negative control trial for FMT in UC

When to withdraw therapy in crohn's disease?

Proactive TDM or SOC for monitoring infliximab…

The interleukin-17 conundrum

FMT in UC - still far away from the success story

Ustekinumab for fistulizing disease

Un essai négatif sur la transplantation de microbiote…

Una nuova opportunità per i TDM nel controllo proattivo…

Wann Beendigung von Infliximab oder Immunmodulatoren…

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…

Du nouveau sur l’allégement thérapeutique au cours de…

Προληπτική μέτρηση των θεραπευτικών επιπέδων του…

Ist der Therapiestopp eine Option in CD?

Kombination von Biologika - endlich bei IBD…

Combinazione di biologici

FMT ist kein vielversprechender Ansatz für UC-Patienten

מחקר SPARE ב ECCO 2022

Allons nous améliorer la prise en charge des MICI en…

Das Interleukin-17 Rätsel

Il primo trial di terapia biologica di combinazione

Can we translate rheumatoid arthritis to ulcerative…

COVID-19: still a moving target!

Is combination therapy safe?

Which IBD patients have a higher risk of safety…

The heart is apparently safe with continuous Ozanimod…

A touch of the near future in IBD treatment

Il cuore sembra essere apparentemente al sicuro durante…

Uno sguardo al prossimo futuro nel trattamento delle…

Mucosal healing: Will efficacy data translate into real…

Efficacy update on JAKis

Fistulizing Crohn‘s disease - new treatment options…

The race is on IL-23 – exciting data for CD and UC

Vedolizumab in chronic pouchitis - a new chapter in…

Upadacitinib - will it be the game changer in UC?

JAK inhibition

Vedolizumab is effective in chronic pouchitis after…

New opportunity in pouchitis treatment

Anti-IL-23 - a turning point?

New ways of treatment

Guselkumab as maintenace treatment in Crohn's Disease

Selective IL-23 blockade

Selektive IL-23 Blockade

Una nuova opportunità nel trattamemto della pouchite

Wedolizumab w pouchitis - początek nowego rozdziału w…

Upadacitinib - nowy lek, duże nadzieje

JAK-Inhibition

Anti-IL-23 - eine Zeitenwende?

Guselkumab come terapia di mantenimento

New therapeutic goals in UC

Disease control is possible!

New therapy goals: urgency and disease clearance

Natural history of anal ulcerations in pediatric-onset…

Patient relevant outcomes also show efficacy of…

Histological findings in mirikizumab treatment

Urgency und Disease Clearance

Nuevas objetivos en las EII

Disease Control ist möglich!

The efficacy of COVID-19 vaccines in IBD - what's new?

Skuteczność szczepień przeciw COVID-19 w IBD - nowe…

Point of Care Testing / AI / Telemedicine

Ultraschall als Prädiktor des Therapieansprechens

Spanish women leading contribution to ECCO 2022

Las mujeres lideran la contribución española a la ECCO…